#biotech #Vaderis #Aureka #Epicrispr #Infinimmune #BoulevardBio #VaderisTherapeutics #AI #AurekaBiotechnologies #labintheloopplatform #AIenableddrugdiscovery #AuraIDE #EpicrisprBiotechnologies #epigenetictherapy #FSHD #atopicdermatitis #clinicaldevelopment #IgAnephropathy #IgAN
zurl.co/pUysi
zurl.co/pUysi
Which biotechs have raised new VC financing this week?
Our round-up of venture capital financings in biotech this week features Vaderis, Aureka, Epicrispr, Infinimmune, and Boulevard Bio.
pharmaphorum.com
August 18, 2026 at 11:26 AM
Há algum tempo novas #espécies têm sido batizadas com nomes de celebridades ou personagens. Muitas vezes isso ocorre porque o pesquisador é fã daquela figura, contudo, alguns cientistas acreditam que é preciso popularizar a ciência. Quem não vai ficar curioso para conhecer o #crustáceo #DarthVader?!
Com cabeça que lembra capacete de Darth Vader, nova espécie de crustáceo gigante ganha nome de 'Vaderis'
Isópode foi descoberto no Vietnã e faz parte de um grupo de animais que pode passar dos 30 centímetros e pesar mais do que 1 kg. Há algum tempo algumas das novas espécies descritas na biologia têm sid...
conexaoplaneta.com.br
January 14, 2025 at 11:32 PM
Há algum tempo novas #espécies têm sido batizadas com nomes de celebridades ou personagens. Muitas vezes isso ocorre porque o pesquisador é fã daquela figura, contudo, alguns cientistas acreditam que é preciso popularizar a ciência. Quem não vai ficar curioso para conhecer o #crustáceo #DarthVader?!
📰 Healthcare & Pharma — Daily Briefing
Biotech funding stays robust: InduPro raised $77M and Vaderis closed a $152M Series B. Rigel's Veppanu is now available in the US, adding a commercial catalyst. Eugia Pharma's ($AUROPHARMA) FDA warning letter flags manufacturing risk.
Biotech funding stays robust: InduPro raised $77M and Vaderis closed a $152M Series B. Rigel's Veppanu is now available in the US, adding a commercial catalyst. Eugia Pharma's ($AUROPHARMA) FDA warning letter flags manufacturing risk.
August 14, 2026 at 12:00 PM
📰 Healthcare & Pharma — Daily Briefing
Biotech funding stays robust: InduPro raised $77M and Vaderis closed a $152M Series B. Rigel's Veppanu is now available in the US, adding a commercial catalyst. Eugia Pharma's ($AUROPHARMA) FDA warning letter flags manufacturing risk.
Biotech funding stays robust: InduPro raised $77M and Vaderis closed a $152M Series B. Rigel's Veppanu is now available in the US, adding a commercial catalyst. Eugia Pharma's ($AUROPHARMA) FDA warning letter flags manufacturing risk.
Our members Almac Discovery are so cool because their originated molecule advanced to global phase 3 study (!!) after their significant development milestone for Vaderis Therapeutics everyone say heck yeah Almac Discovery
September 14, 2026 at 11:00 AM
Our members Almac Discovery are so cool because their originated molecule advanced to global phase 3 study (!!) after their significant development milestone for Vaderis Therapeutics everyone say heck yeah Almac Discovery
InduPro and Vaderis secure substantial funding in latest rounds: $77M and $152M series B respectively. These investments will support their expansion efforts and innovative developments in the biotech sector.
August 14, 2026 at 1:03 PM
InduPro and Vaderis secure substantial funding in latest rounds: $77M and $152M series B respectively. These investments will support their expansion efforts and innovative developments in the biotech sector.
Our round-up of #venturecapital #financings in #biotech this week is headed by a $152 million round for #Vaderis, with #Aureka, #Epicrispr, #Infinimmune, and #BoulevardBio featured.
buff.ly/Fn1Mi83
buff.ly/Fn1Mi83
August 14, 2026 at 9:30 AM
Our round-up of #venturecapital #financings in #biotech this week is headed by a $152 million round for #Vaderis, with #Aureka, #Epicrispr, #Infinimmune, and #BoulevardBio featured.
buff.ly/Fn1Mi83
buff.ly/Fn1Mi83
Vaderis gets $152M boost as vascular disorder drug starts Phase III firstwordpharma.com/story/7838373
August 11, 2026 at 11:13 PM
Vaderis gets $152M boost as vascular disorder drug starts Phase III firstwordpharma.com/story/7838373
HHT Patients Get First Phase 3 Drug Trial After 130 Years Without Treatment
Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152…
Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152…
HHT Patients Get First Phase 3 Drug Trial After 130 Years Without Treatment
Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152 million in new funding and proof-of-concept data showing 41% bleeding reduction published in the New England Journal of Medicine.
news-area.com
August 12, 2026 at 2:57 AM
HHT Patients Get First Phase 3 Drug Trial After 130 Years Without Treatment
Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152…
Hereditary hemorrhagic telangiectasia has never had an approved treatment anywhere in the world -- until now, Vaderis Therapeutics launched HEROIC, the first-ever global Phase 3 clinical trial for HHT, backed by $152…
Vaderis raised $152M to push a repurposed cancer drug into Phase 3 for a rare bleeding disorder with no approved treatments.
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
endpoints.news
August 11, 2026 at 1:32 PM
Vaderis raised $152M to push a repurposed cancer drug into Phase 3 for a rare bleeding disorder with no approved treatments.
Vaderis Therapeutics Secures $152 Million in Series B Financing for Engasertib and Launches Phase 3 HEROIC Study#USA#Lincolnshire#HHT#engasertib#Vaderis
Vaderis Therapeutics Secures $152 Million in Series B Financing for Engasertib and Launches Phase 3 HEROIC Study
Vaderis Therapeutics has successfully closed a $152 million Series B financing round, launching the Phase 3 HEROIC study for engasertib aimed at treating HHT.
third-news.com
August 11, 2026 at 11:19 AM
Vaderis Therapeutics Secures $152 Million in Series B Financing for Engasertib and Launches Phase 3 HEROIC Study#USA#Lincolnshire#HHT#engasertib#Vaderis
Vaderis Therapeutics Secures $152 Million in Financing and Begins HEROIC Study for HHT Treatment#USA#Lincolnshire#HHT#Vaderis_Therapeutics#engasertib
Vaderis Therapeutics Secures $152 Million in Financing and Begins HEROIC Study for HHT Treatment
Vaderis Therapeutics has successfully raised $152 million in Series B funding, enabling the start of the HEROIC Phase 3 study for engasertib, targeting hereditary hemorrhagic telangiectasia.
third-news.com
August 11, 2026 at 11:12 AM
Vaderis Therapeutics Secures $152 Million in Financing and Begins HEROIC Study for HHT Treatment#USA#Lincolnshire#HHT#Vaderis_Therapeutics#engasertib
EQT Life Sciences Invests in Vaderis Therapeutics' Series B Financing Round#Sweden#Stockholm#EQT_Life_Sciences#Vaderis_Therapeutics#engasertib
EQT Life Sciences Invests in Vaderis Therapeutics' Series B Financing Round
EQT Life Sciences has invested $17.5 million in Vaderis Therapeutics as part of a $152 million Series B round aimed at advancing groundbreaking treatments for rare diseases.
third-news.com
August 11, 2026 at 12:02 PM
EQT Life Sciences Invests in Vaderis Therapeutics' Series B Financing Round#Sweden#Stockholm#EQT_Life_Sciences#Vaderis_Therapeutics#engasertib
Biotech IPO window reopens: Vaderis ($152M B), Epicrispr ($90M), Infinimmune ($75M A, Regeneron-backed). FDA rejects ITM radiopharma and Scholar Rock SMA filing; BMS commits $2.3B to Houston plant. 38 articles, 8 sources.
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-11/
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-11/
August 12, 2026 at 2:09 AM
Biotech IPO window reopens: Vaderis ($152M B), Epicrispr ($90M), Infinimmune ($75M A, Regeneron-backed). FDA rejects ITM radiopharma and Scholar Rock SMA filing; BMS commits $2.3B to Houston plant. 38 articles, 8 sources.
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-11/
https://openbionews.com/analysis/daily-bio-news-summary-2026-08-11/
A #clinicaltrial of #VaderisTherapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for #hereditaryhaemorrhagictelangiectasia (HHT), the second most common #inheritedbleedingdisorder.
Vaderis drug lends hope to patients with bleeding disease HHT
A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.
buff.ly
November 27, 2025 at 4:00 PM
A #clinicaltrial of #VaderisTherapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for #hereditaryhaemorrhagictelangiectasia (HHT), the second most common #inheritedbleedingdisorder.
Years of scientific work deserves a presentation that feels complete. Grateful for the partnership with Vaderis and proud to support #MedicalAffairs teams when the stakes are high. Learn more: http://bit.ly/1yAtqEj
March 25, 2026 at 10:02 PM
Years of scientific work deserves a presentation that feels complete. Grateful for the partnership with Vaderis and proud to support #MedicalAffairs teams when the stakes are high. Learn more: http://bit.ly/1yAtqEj
Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT
www.viv-media.com
August 27, 2024 at 2:12 PM